Deerfield Management’s Sarepta Therapeutics SRPT Stock Holding History

Deerfield Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-141,000	Closed	-$12.7M	–	131
2021 Q4	$12.7M	Buy	+141,000	New	+$12.1M	0.27%	76
2020 Q2	–	Sell	-235,000	Closed	-$23M	–	100
2020 Q1	$23M	Buy	235,000 +25,000	+12%	+$2.86M	0.73%	45
2019 Q4	$27.1M	Sell	210,000 -172,000	-45%	-$17.4M	0.86%	38
2019 Q3	$28.8M	Buy	382,000 +72,975	+24%	+$8.62M	1.17%	26
2019 Q2	$47M	Sell	309,025 -76,975	-20%	-$9.36M	1.69%	16
2019 Q1	$46M	Buy	386,000 +44,200	+13%	+$5.68M	1.76%	17
2018 Q4	$37.3M	Buy	341,800 +45,800	+15%	+$5.73M	1.49%	22
2018 Q3	$47.8M	Hold	296,000	–	–	1.71%	19
2018 Q2	$39.1M	Buy	+296,000	New	+$27.9M	1.37%	22

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management's SRPT Position: Q1 2022 in Review

Deerfield Management sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 141,000 shares — an estimated $12.7M sold.

Deerfield Management first reported a position in SRPT in Q2 2018 and held it in 9 quarters. The position peaked at $47.8M in Q3 2018. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

Deerfield Management reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
Deerfield Management sold 141,000 Sarepta Therapeutics shares in Q1 2022, an estimated $12.7M.
Deerfield Management first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 9 quarters.
Deerfield Management's Sarepta Therapeutics position peaked at $47.8M in Q3 2018.
328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Deerfield Management's 13F filing for Q1 2022, filed 16 May 2022.